|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pham T, Bui L, Kim G, Hoang D, Tran T and
Hoang M: Cancers in Vietnam-burden and control efforts: a narrative
scoping review. Cancer Contr. 26:1073274819863802. 2019.
|
|
3
|
Fearon ER and Vogelstein B: A genetic
model for colorectal tumorigenesis. Cell. 61:759–767. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Vogelstein B and Kinzler KW: Cancer genes
and the pathways they control. Nat Med. 10:789–799. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nguyen HT and Duong HQ: The molecular
characteristics of colorectal cancer: Implications for diagnosis
and therapy (Review). Oncol Lett. 16:9–18. 2018.PubMed/NCBI
|
|
6
|
Brenner H, Kloor M and Pox CP: Colorectal
cancer. Lancet. 383:1490–1502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Grady WM and Carethers JM: Genomic and
epigenetic instability in colorectal cancer pathogenesis.
Gastroenterology. 135:1079–1099. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Markowitz SD and Bertagnolli MM: Molecular
origins of cancer: Molecular basis of colorectal cancer. N Engl J
Med. 361:2449–2460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sinicrope FA and Sargent DJ: Molecular
pathways: microsatellite instability in colorectal cancer:
prognostic, predictive, and therapeutic implications. Clin Cancer
Res. 18:1506–1512. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Worthley DL and Leggett BA: Colorectal
cancer: Molecular features and clinical opportunities. Clin Biochem
Rev. 31:31–38. 2010.PubMed/NCBI
|
|
11
|
Weisenberger DJ, Siegmund KD, Campan M,
Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D,
Buchanan D, et al: CpG island methylator phenotype underlies
sporadic microsatellite instability and is tightly associated with
BRAF mutation in colorectal cancer. Nat Genet. 38:787–793. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Abdel-Rahman WM and Peltomäki P: Molecular
basis and diagnostics of hereditary colorectal cancers. Ann Med.
36:379–388. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Pawlik TM, Raut CP and Rodriguez-Bigas MA:
Colorectal carcinogenesis: MSI-H versus MSI-L. Dis Markers.
20:199–206. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Benatti P, Gafà R, Barana D, Marino M,
Scarselli A, Pedroni M, Maestri I, Guerzoni L, Roncucci L,
Menigatti M, et al: Microsatellite instability and colorectal
cancer prognosis. Clin Cancer Res. 11:8332–8340. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Popat S, Hubner R and Houlston RS:
Systematic review of microsatellite instability and colorectal
cancer prognosis. J Clin Oncol. 23:609–618. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Samowitz WS, Albertsen H, Herrick J, Levin
TR, Sweeney C, Murtaugh MA, Wolff RK and Slattery ML: Evaluation of
a large, population-based sample supports a CpG island methylator
phenotype in colon cancer. Gastroenterology. 129:837–845. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sinicrope FA and Sargent DJ: Clinical
implications of microsatellite instability in sporadic colon
cancers. Curr Opin Oncol. 21:369–373. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wee P and Wang Z: Epidermal growth factor
receptor cell proliferation signaling pathways. Cancers (Basel).
9:1–45. 2017.
|
|
19
|
Fernández-Medarde A and Santos E: Ras in
cancer and developmental diseases. Genes Cancer. 2:344–358. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Neumann J, Zeindl-Eberhart E, Kirchner T
and Jung A: Frequency and type of KRAS mutations in routine
diagnostic analysis of metastatic colorectal cancer. Pathol Res
Pract. 205:858–862. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kosmidou V, Oikonomou E, Vlassi M,
Avlonitis S, Katseli A, Tsipras I, Mourtzoukou D, Kontogeorgos G,
Zografos G and Pintzas A: Tumor heterogeneity revealed by KRAS,
BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor
mutation profile differences and their therapeutic implications.
Hum Mutat. 35:329–340. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schubbert S, Shannon K and Bollag G:
Hyperactive Ras in developmental disorders and cancer. Nat Rev
Cancer. 7:295–308. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Rajagopalan H, Bardelli A, Lengauer C,
Kinzler KW, Vogelstein B and Velculescu VE: Tumorigenesis: RAF/RAS
oncogenes and mismatch-repair status. Nature. 418:9342002.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yuen ST, Davies H, Chan TL, Ho JW, Bignell
GR, Cox C, Stephens P, Edkins S, Tsui WW, Chan AS, et al:
Similarity of the phenotypic patterns associated with BRAF and KRAS
mutations in colorectal neoplasia. Cancer Res. 62:6451–6455.
2002.PubMed/NCBI
|
|
25
|
De Roock W, Claes B, Bernasconi D, De
Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V,
Papamichael D, Laurent-Puig P, et al: Effects of KRAS, BRAF, NRAS,
and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy
in chemotherapy-refractory metastatic colorectal cancer: A
retrospective consortium analysis. Lancet Oncol. 11:753–762. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Calistri D, Rengucci C, Seymour I,
Leonardi E, Truini M, Malacarne D, Castagnola P and Giaretti W:
KRAS, p53 and BRAF gene mutations and aneuploidy in sporadic
colorectal cancer progression. Cell Oncol. 28:161–166.
2006.PubMed/NCBI
|
|
27
|
Cantwell-Dorris ER, O'Leary JJ and Sheils
OM: BRAFV600E: Implications for carcinogenesis and molecular
therapy. Mol Cancer Ther. 10:385–394. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Amado RG, Wolf M, Peeters M, Van Cutsem E,
Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et
al: Wild-type KRAS is required for panitumumab efficacy in patients
with metastatic colorectal cancer. J Clin Oncol. 26:1626–1634.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Di Nicolantonio F, Martini M, Molinari F,
Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L,
Frattini M, Siena S, et al: Wild-type BRAF is required for response
to panitumumab or cetuximab in metastatic colorectal cancer. J Clin
Oncol. 26:5705–5712. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD,
Robitaille S, et al: K-ras mutations and benefit from cetuximab in
advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bardelli A and Siena S: Molecular
mechanisms of resistance to cetuximab and panitumumab in colorectal
cancer. J Clin Oncol. 28:1254–1261. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
van Brummelen EMJ, de Boer A, Beijnen JH
and Schellens JHM: BRAF mutations as predictive biomarker for
response to anti-EGFR monoclonal antibodies. Oncologist.
22:864–872. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhao B, Wang L, Qiu H, Zhang M, Sun L,
Peng P, Yu Q and Yuan X: Mechanisms of resistance to anti-EGFR
therapy in colorectal cancer. Oncotarget. 8:3980–4000. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Borràs E, Jurado I, Hernan I, Gamundi MJ,
Dias M, Martí I, Mañé B, Arcusa A, Agúndez JAG, Blanca M, et al:
Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations
by high resolution melting analysis and ultra-deep pyrosequencing.
BMC Cancer. 11:4062011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mohamed Suhaimi NA, Foong YM, Lee DYS,
Phyo WM, Cima I, Lee EXW, Goh WL, Lim WY, Chia KS, Kong SL, et al:
Non-invasive sensitive detection of KRAS and BRAF mutation in
circulating tumor cells of colorectal cancer patients. Mol Oncol.
9:850–860. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sclafani F, Chau I, Cunningham D, Hahne
JC, Vlachogiannis G, Eltahir Z, Lampis A, Braconi C, Kalaitzaki E,
De Castro DG, et al: KRAS and BRAF mutations in circulating tumour
DNA from locally advanced rectal cancer. Sci Rep. 8:14452018.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nguyen HT, Geens M, Mertzanidou A, Jacobs
K, Heirman C, Breckpot K and Spits C: Gain of 20q11.21 in human
embryonic stem cells improves cell survival by increased expression
of Bcl-xL. Mol Hum Reprod. 20:168–177. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Boland CR, Thibodeau SN, Hamilton SR,
Sidransky D, Eshleman JR, Burt RW, Meltzer SJ, Rodriguez-Bigas MA,
Fodde R, Ranzani GN and Srivastava S: A National Cancer Institute
Workshop on Microsatellite Instability for cancer detection and
familial predisposition: development of international criteria for
the determination of microsatellite instability in colorectal
cancer. Cancer Res. 58:5248–5257. 1998.PubMed/NCBI
|
|
39
|
Findeisen P, Kloor M, Merx S, Sutter C,
Woerner SM, Dostmann N, Benner A, Dondog B, Pawlita M, Dippold W,
et al: T25 repeat in the 3′ untranslated region of the CASP2 gene:
A sensitive and specific marker for microsatellite instability in
colorectal cancer. Cancer Res. 65:8072–8078. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Nguyen HT, Markouli C, Geens M, Barbé L,
Sermon K and Spits C: Human embryonic stem cells show low-grade
microsatellite instability. Mol Hum Reprod. 20:981–989. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Skotheim RI, Diep CB, Kraggerud SM,
Jakobsen KS and Lothe RA: Evaluation of loss of
heterozygosity/allelic imbalance scoring in tumor DNA. Cancer Genet
Cytogenet. 127:64–70. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Heaphy CM, Hines WC, Butler KS, Haaland
CM, Heywood G, Fischer EG, Bisoffi M and Griffith JK: Assessment of
the frequency of allelic imbalance in human tissue using a
multiplex polymerase chain reaction system. J Mol Diagn. 9:266–271.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Gilder JR, Inman K, Shields W and Krane
DE: Magnitude-dependent variation in peak height balance at
heterozygous STR loci. Int J Legal Med. 125:87–94. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Leclair B, Frégeau CJ, Bowen KL and
Fourney RM: Systematic analysis of stutter percentages and allele
peak height and peak area ratios at heterozygous STR loci for
forensic casework and database samples. J Forensic Sci. 49:968–980.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Sinicrope FA, Foster NR, Thibodeau SN,
Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C,
Moore MJ, et al: DNA mismatch repair status and colon cancer
recurrence and survival in clinical trials of 5-fluorouracil-based
adjuvant therapy. J Natl Cancer Inst. 103:863–875. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Roth AD, Delorenzi M, Tejpar S, Yan P,
Klingbiel D, Fiocca R, d'Ario G, Cisar L, Labianca R, Cunningham D,
et al: Integrated analysis of molecular and clinical prognostic
factors in stage II/III colon cancer. J Natl Cancer Inst.
104:1635–1646. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Klingbiel D, Saridaki Z, Roth AD, Bosman
FT, Delorenzi M and Tejpar S: Prognosis of stage II and III colon
cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation
to microsatellite status: Results of the PETACC-3 trial. Ann Oncol.
26:126–132. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Allegra CJ, Jessup JM, Somerfield MR,
Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF and
Schilsky RL: American Society of Clinical Oncology provisional
clinical opinion: Testing for KRAS gene mutations in patients with
metastatic colorectal carcinoma to predict response to
anti-epidermal growth factor receptor monoclonal antibody therapy.
J Clin Oncol. 27:2091–2096. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Van Cutsem E, Köhne CH, Láng I, Folprecht
G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D,
Tejpar S, et al: Cetuximab plus irinotecan, fluorouracil, and
leucovorin as first-line treatment for metastatic colorectal
cancer: Updated analysis of overall survival according to tumor
KRAS and BRAF mutation status. J Clin Oncol. 29:2011–2019. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Douillard JY, Oliner KS, Siena S,
Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham
D, Jassem J, et al: Panitumumab-FOLFOX4 treatment and RAS mutations
in colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ashktorab H, Smoot DT, Carethers JM,
Rahmanian M, Kittles R, Vosganian G, Doura M, Nidhiry E, Naab T,
Momen B, et al: High incidence of microsatellite instability in
colorectal cancer from African Americans. Clin Cancer Res.
9:1112–1117. 2003.PubMed/NCBI
|
|
52
|
Salto-Tellez M, Tan SY, Chiu LL and Koay
ESC: Dinucleotide microsatellite repeats are essential for the
diagnosis of microsatellite instability in colorectal cancer in
Asian patients. World J Gastroenterol. 11:2781–2783. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Asaka S, Arai Y, Nishimura Y, Yamaguchi K,
Ishikubo T, Yatsuoka T, Tanaka Y and Akagi K: Microsatellite
instability-low colorectal cancer acquires a KRAS mutation during
the progression from Dukes' A to Dukes' B. Carcinogenesis.
30:494–499. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yamada K, Kanazawa S, Koike J, Sugiyama H,
Xu C, Funahashi K, Boland CR, Koi M and Hemmi H: Microsatellite
instability at tetranucleotide repeats in sporadic colorectal
cancer in Japan. Oncol Rep. 23:551–561. 2010.PubMed/NCBI
|
|
55
|
Kim CG, Ahn JB, Jung M, Beom SH, Kim C,
Kim JH, Heo SJ, Park HS, Kim JH, Kim NK, et al: Effects of
microsatellite instability on recurrence patterns and outcomes in
colorectal cancers. Br J Cancer. 115:25–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Woerner SM, Benner A, Sutter C, Schiller
M, Yuan YP, Keller G, Bork P, Doeberitz M and Gebert JF:
Pathogenesis of DNA repair-deficient cancers: A statistical
meta-analysis of putative Real Common Target genes. Oncogene.
22:2226–2235. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yamamoto H, Adachi Y, Taniguchi H,
Kunimoto H, Nosho K, Suzuki H and Shinomura Y: Interrelationship
between microsatellite instability and microRNA in gastrointestinal
cancer. World J Gastroenterol. 18:2745–2755. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Poynter JN, Siegmund KD, Weisenberger DJ,
Long TI, Thibodeau SN, Lindor N, Young J, Jenkins MA, Hopper JL,
Baron JA, et al Colon Cancer Family Registry Investigators, :
Molecular characterization of MSI-H colorectal cancer by MLHI
promoter methylation, immunohistochemistry, and mismatch repair
germline mutation screening. Cancer Epidemiol Biomarkers Prev.
17:3208–3215. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Kim GP, Colangelo LH, Wieand HS, Paik S,
Kirsch IR, Wolmark N and Allegra CJ; National Cancer Institute, :
Prognostic and predictive roles of high-degree microsatellite
instability in colon cancer: a National Cancer Institute-National
Surgical Adjuvant Breast and Bowel Project Collaborative Study. J
Clin Oncol. 25:767–772. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Thibodeau SN, Bren G and Schaid D:
Microsatellite instability in cancer of the proximal colon.
Science. 260:816–819. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Cho YK, Kim HC, Kim SH, Park JH, Yun HR,
Cho YB, Yun SH, Lee WY and Chun HK: Location-related differences in
sporadic microsatellite unstable colorectal cancer. Dig Liver Dis.
42:611–615. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yang Y, Wang G, He J, Ren S, Wu F, Zhang J
and Wang F: Gender differences in colorectal cancer survival: A
meta-analysis. Int J Cancer. 141:1942–1949. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Gryfe R, Kim H, Hsieh ETK, Aronson MD,
Holowaty EJ, Bull SB, Redston M and Gallinger S: Tumor
microsatellite instability and clinical outcome in young patients
with colorectal cancer. N Engl J Med. 342:69–77. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Van Cutsem E, Köhne CH, Hitre E, Zaluski
J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G,
et al: Cetuximab and chemotherapy as initial treatment for
metastatic colorectal cancer. N Engl J Med. 360:1408–1417. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Roth AD, Tejpar S, Delorenzi M, Yan P,
Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C,
et al: Prognostic role of KRAS and BRAF in stage II and III
resected colon cancer: Results of the translational study on the
PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 28:466–474.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Yokota T: Are KRAS/BRAF mutations potent
prognostic and/or predictive biomarkers in colorectal cancers?
Anticancer Agents Med Chem. 12:163–171. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Vaughn CP, Zobell SD, Furtado LV, Baker CL
and Samowitz WS: Frequency of KRAS, BRAF, and NRAS mutations in
colorectal cancer. Genes Chromosomes Cancer. 50:307–312. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Peeters M, Kafatos G, Taylor A, Gastanaga
VM, Oliner KS, Hechmati G, Terwey JH and van Krieken JH: Prevalence
of RAS mutations and individual variation patterns among patients
with metastatic colorectal cancer: A pooled analysis of randomised
controlled trials. Eur J Cancer. 51:1704–1713. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Guo F, Gong H, Zhao H, Chen J, Zhang Y,
Zhang L, Shi X, Zhang A, Jin H, Zhang J, et al: Mutation status and
prognostic values of KRAS, NRAS, BRAF and PIK3CA in 353 Chinese
colorectal cancer patients. Sci Rep. 8:60762018. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Loupakis F, Ruzzo A, Cremolini C, Vincenzi
B, Salvatore L, Santini D, Masi G, Stasi I, Canestrari E, Rulli E,
et al: KRAS codon 61, 146 and BRAF mutations predict resistance to
cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type
metastatic colorectal cancer. Br J Cancer. 101:715–721. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Peeters M, Douillard JY, Van Cutsem E,
Siena S, Zhang K, Williams R and Wiezorek J: Mutant KRAS codon 12
and 13 alleles in patients with metastatic colorectal cancer:
Assessment as prognostic and predictive biomarkers of response to
panitumumab. J Clin Oncol. 31:759–765. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Hsu HC, Thiam TK, Lu YJ, Yeh CY, Tsai WS,
You JF, Hung HY, Tsai CN, Hsu A, Chen HC, et al: Mutations of
KRAS/NRAS/BRAF predict cetuximab resistance in metastatic
colorectal cancer patients. Oncotarget. 7:22257–22270. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Li HT, Lu YY, An YX, Wang X and Zhao QC:
KRAS, BRAF and PIK3CA mutations in human colorectal cancer:
Relationship with metastatic colorectal cancer. Oncol Rep.
25:1691–1697. 2011.PubMed/NCBI
|
|
74
|
Hu J, Yan WY, Xie L, Cheng L, Yang M, Li
L, Shi J, Liu BR and Qian XP: Coexistence of MSI with KRAS mutation
is associated with worse prognosis in colorectal cancer. Medicine
(Baltimore). 95:e56492016. View Article : Google Scholar : PubMed/NCBI
|
